Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824

Cancer Research

Volumn 64, Issue 2, 2004, Pages 689-695

  Atadja, Peter ^a   Gao, Lin ^a   Kwon, Paul ^a   Trogani, Nancy ^a   Walker, Heather ^a   Hsu, Meier ^a   Yeleswarapu, Lakshmi ^a   Chandramouli, Nagarajan ^a   Perez, Larry ^a   Versace, Richard ^a   Wu, Arthur ^a   Sambucetti, Lidia ^a   Lassota, Peter ^a   Cohen, Dalia ^a   Bair, Kenneth ^a   Wood, Alexander ^a   Remiszewski, Stacy ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; CINNAMIC ACID DERIVATIVE; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; HYDROXAMIC ACID DERIVATIVE; LIPOCORTIN 5; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL POPULATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; COLONIC NEOPLASMS; ENZYME INHIBITORS; FLUOROURACIL; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; KINETICS; MALE; MICE; PROMOTER REGIONS (GENETICS); TRANSPLANTATION, HETEROLOGOUS;

EID: 9144225360     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2043     Document Type: Article

References (41)

1. Struhl, K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev., 12: 599-606, 1998.
2. Corn, P. G., Kuerbitz, S. J., van Noesel, M. M., Esteller, M., Compitello, N., Baylin, S. B., and Herman, J. G. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res., 59: 3352-3356, 1999.
3. Domann, F. E., Rice, J. C., Hendrix, M. J., and Futscher, B. W. Epigenetic silencing of maspin gene expression in human breast cancers. Int. J. Cancer, 85: 805-810, 2000.
4. Schagdarsurengin, U., Gimm, O., Hoang-Vu, C., Dralle, H., Pfeifer, G. P., and Dammann, R. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res., 62: 3698-3701, 2002.
5. van Engeland, M., Roemen, G. M., Brink, M., Pachen, M. M., Weijenberg, M. P., de Bruine, A. P., Arends, J. W., van den Brandt, P. A., de Goeij, A. F., and Herman, J. G. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene, 21: 3792-3795, 2002.
6. Gasco, M., Sullivan, A., Repellin, C., Brooks, L., Farrell, P. J., Tidy, J. A., Dunne, B., Gusterson, B., Evans, D. J., and Crook, T. Coincident inactivation of 14-3-3σ and p16INK4a is an early event in vulval squamous neoplasia. Oncogene, 21: 1876-1881, 2002.
7. Sharpless, N. E., Bardeesy, N., Lee, K. H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., and DePinho, R. A. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature (Lond.), 413: 86-91, 2001.
8. Yanagawa, N., Tamura, G., Oizumi, H., Takahashi, N., Shimazaki, Y., and Motoyama, T. Frequent epigenetic silencing of the p16 gene in non-small cell lung cancers of tobacco smokers. Jpn. J. Cancer Res., 93: 1107-1113, 2002.
9. Boivin, A. J., Momparler, L. F., Hurtubise, A., and Momparler, R. L. Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs, 13: 869-874, 2002.
10. Shinagawa, T., Nomura, T., Colmenares, C., Ohira, M., Nakagawara, A., and Ishii, S. Increased susceptibility to tumorigenesis of ski-deficient heterozygous mice. Oncogene, 20: 8100-8108, 2001.
11. Won, J., Yim, J., and Kim, T. K. Sp1 and Sp3 recruit histone deacetylase to repress transcription of human telomerase reverse transcriptase (hTERT) promoter in normal human somatic cells. J. Biol. Chem., 277: 38230-38238, 2002.
12. Han, J. W., Ahn, S. H., Park, S. H., Wang, S. Y., Bae, G. U., Seo, D. W., Kwon, H. K., Hong, S., Lee, H. Y., Lee, Y. W., and Lee, H. W. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res., 60: 6068-6074, 2000.
13. Marks, P. A., Richon, V. M., and Rifkind, R. A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst., 92: 1210-1216, 2000.
14. Greenberg, V. L., Williams, J. M., Cogswell, J. P., Mendenhall, M., and Zimmer, S. G. Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. Thyroid, 11: 315-325, 2001.
15. Jaboin, J., Wild, J., Hamidi, H., Khanna, C., Kim, C. J., Robey, R., Bates, S. E., and Thiele, C. J. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res., 62: 6108-6115, 2002.
16. Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., and Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA, 98: 87-92, 2001.
17. Fournel, M., Trachy-Bourget, M. C., Yan, P. T., Kalita, A., Bonfils, C., Beaulieu, C., Frechette, S., Leit, S., Abou-Khalil, E., Woo, S. H., Delorme, D., MacLeod, A. R., Besterman, J. M., and Li, Z. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res., 62: 4325-4330, 2002.
18. Kim, Y. B., Ki, S. W., Yoshida, M., and Horinouchi, S. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human cateinoma cells. J. Antibiot. (Tokyo), 53: 1191-1200, 2000.
19. Richon, V. M., Zhou, X., Rifkind, R. A., and Marks, P. A. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol. Dis., 27: 260-264, 2001.
20. Sambucetti, L. C., Fischer, D. D., Zabludoff, S., Kwon, P. O., Chamberlin, H., Trogani, N., Xu, H., and Cohen, D. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem., 274: 34940-34947, 1999.
21. Strait, K. A., Dabbas, B., Hammond, E. H., Warnick, C. T., Iistrup, S. J., and Ford, C. D. Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol. Cancer Ther., 1: 1181-1190, 2002.
22. Slack, J. L. The biology and treatment of acute progranulocytic leukemia. Curr. Opin. Oncol., 11: 9-13, 1999.
23. Amann, J. M., Nip, J., Strom, D. K., Lutterbach, B., Harada, H., Lenny, N., Downing, J. R., Meyers, S., and Hiebert, S. W. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell. Biol., 21: 6470-6483, 2001.
24. Gelmetti, V., Zhang, J., Fanelli, M., Minucci, S., Pelicci, P. G., and Lazar, M. A. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol. Cell. Biol., 18: 7185-7191, 1998.
25. Ferrara, F. F., Fazi, F., Bianchini, A., Padula, F., Gehnetti, V., Minucci, S., Mancini, M, Pelicci, P. G., Lo, C. F., and Nervi, C. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res., 61: 2-7, 2001.
26. Petti, M. C., Fazi, F., Gentile, M., Diverio, D., De Fabritiis, P., De Propris, M. S., Fiorini, R., Spiriti, M. A., Padula, F., Pelicci, P. G., Nervi, C., and Lo, C. F. Complete remission through blast cell differentiation in PLZF/RARα-positive acute promyelocytic leukemia: in vitro and in vivo studies. Blood, 10: 1065-1067, 2002.
27. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., and Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA, 96: 4592-4597, 1999.
28. Lavelle, D., Chen, Y. H., Hankewych, M., and DeSimone, J. Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am. J. Hematol., 68: 170-178, 2001.
29. Suzuki, T., Yokozaki, H., Kuniyasu, H., Hayashi, K., Naka, K., Ono, S., Ishikawa, T., Tahara, E., and Yasui, W. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int. J. Cancer, 88: 992-997, 2000.
30. Richon, V. M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R. A., and Marks, P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA, 93(12): 5705-5708, 1996.
31. Pina, I. C., Gautschi, J. T., Wang, G. Y., Sanders, M. L., Schmitz, F. J., France, D., Cornell-Kennon, S., Sambucetti, L. C., Remiszewski, S. W., Perez, L. B., Bair, K. W., and Crews, P. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem., 68(10): 3866-3873, 2003.
32. Remiszewski, S. W. The discovery of NVP-LAQ824: from concept to clinic. Curr. Med. Chem., 10(22): 2393-402, 2003.
33. Yoshida, M., Furumai, R., Nishiyama, M., Komatsu, Y., Nishino, N., and Horinouchi, S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol., 48 Suppl 1: S20-S26, 2001.
34. Marks, P., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., and Kelly, W. K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1: 194-202, 2001.
35. Pelicci, P. G. A new class of anti-cancer drugs: HDAC-inhibitors. Suppl. Tumori, 1: S66, 2002.
36. Vigushin, D. M., and Coombes, R. C. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs, 13: 1-13, 2002.
37. Sowa, Y., Orita, T., Minamikawa, S., Nakano, K., Mizuno, T., Nomura, H., and Sakai, T. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem. Biophys. Res. Commun., 241: 142-150, 1997.
38. Qiu, L., Burgess, A., Fairlie, D. P., Leonard, H., Parsons, P. G., and Gabrielli, B. G. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell, 11: 2069-2083, 2000.
39. Glick, R. D., Swendeman, S. L., Coffey, D. C., Rifkind, R. A., Marks, P. A., Richon, V. M., and La Quaglia, M. P. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res., 59: 4392-4399, 1999.
40. Inoue, H., Shiraki, K., Ohmori, S., Sakai, T., Deguchi, M., Yamanaka, T., Okano, H., and Nakano, T. Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis. Int. J. Mol. Med., 9: 521-525, 2002.
41. Suzuki, T., Ando, T., Tsuchiya, K., Fukazawa, N., Saito, A., Mariko, Y., Yamashita, T., and Nakanishi, O. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem., 42(15): 3001-3003, 1999.